Peptide vs Monoclonal Antibody — Neurology Deal Terms Comparison
Market Analysis
In neurology, Peptide and Monoclonal Antibody represent two of the most actively transacted modalities. At Phase 2, Peptide deals carry a median total deal value of $3.2B with $361M upfront, compared to $3.1B total value and $354M upfront for Monoclonal Antibody. The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. Peptide development milestones average $934M versus $916M for Monoclonal Antibody. Commercial milestones are $877M for Peptide and $861M for Monoclonal Antibody. Royalty rates range from 12.5%-20.1% for Peptide and 12.5%-20% for Monoclonal Antibody.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do Peptide and Monoclonal Antibody deal terms compare in neurology?
Which modality commands higher royalty rates: Peptide or Monoclonal Antibody?
How do milestone structures differ between Peptide and Monoclonal Antibody?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.